Aigen Investment Management LP Acquires New Position in AstraZeneca PLC (NASDAQ:AZN)

Aigen Investment Management LP bought a new position in shares of AstraZeneca PLC (NASDAQ:AZN) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 3,950 shares of the company’s stock, valued at approximately $308,000.

Several other large investors have also added to or reduced their stakes in AZN. McClarren Financial Advisors Inc. raised its stake in AstraZeneca by 320.8% during the 3rd quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock valued at $25,000 after purchasing an additional 247 shares during the period. GHP Investment Advisors Inc. purchased a new stake in AstraZeneca during the 2nd quarter valued at approximately $26,000. Capital Performance Advisors LLP purchased a new position in shares of AstraZeneca in the third quarter worth $28,000. Pathway Financial Advisers LLC bought a new position in shares of AstraZeneca during the first quarter worth $29,000. Finally, Hobbs Group Advisors LLC purchased a new position in AstraZeneca during the second quarter valued at $35,000. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Wall Street Analyst Weigh In

AZN has been the topic of several research analyst reports. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. TD Cowen increased their price target on AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Finally, Erste Group Bank raised AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, AstraZeneca presently has a consensus rating of “Buy” and an average price target of $89.75.

AstraZeneca Trading Down 2.8 %

Shares of AZN opened at $63.23 on Friday. The company’s fifty day simple moving average is $75.03 and its 200-day simple moving average is $78.20. The company has a market cap of $196.05 billion, a P/E ratio of 30.25, a P/E/G ratio of 1.20 and a beta of 0.47. The company has a current ratio of 0.93, a quick ratio of 0.69 and a debt-to-equity ratio of 0.71. AstraZeneca PLC has a twelve month low of $60.47 and a twelve month high of $87.68.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The company had revenue of $13.57 billion for the quarter, compared to analyst estimates of $13.08 billion. During the same period in the prior year, the company posted $0.87 EPS. The firm’s revenue for the quarter was up 18.0% on a year-over-year basis. As a group, analysts expect that AstraZeneca PLC will post 4.07 EPS for the current year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.